Mohammed Ewid, Suliman Alsagaby, Abdulsalam Al-Ruqi, Odi Al-Shamikh, Abdulelah Aljohani, Mariam Safwan Bourgleh, Moaz Safwana
{"title":"肝硬化心肌病：不同诊断方法患病率的系统回顾和荟萃分析。","authors":"Mohammed Ewid, Suliman Alsagaby, Abdulsalam Al-Ruqi, Odi Al-Shamikh, Abdulelah Aljohani, Mariam Safwan Bourgleh, Moaz Safwana","doi":"10.5144/0256-4947.2025.270","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction associated with liver cirrhosis, yet no consensus exists on standardized diagnostic criteria. We aimed to assess CCM prevalence using several guidelines.</p><p><strong>Methods: </strong>A systematic search of four databases (PubMed, Embase, Google Scholar, and EBSCO) identified observational studies reporting CCM prevalence in cirrhotic patients based on the three criteria: the World Congress of Gastroenterology (Montreal 2005), the American Society of Echocardiography (ASE 2009), and the Cirrhotic Cardiomyopathy Consortium (CCC 2019). A random-effects meta-analysis and subgroup analyses were performed using R Studio.</p><p><strong>Results: </strong>Seventy-six studies including 7445 patients were analyzed. Overall pooled CCM prevalence was 48% (95% CI: 44-52%, I<sup>2</sup>=97%). Prevalence was highest using Montreal 2005 (51%), followed by ASE 2009 (45%) and CCC 2019 (45%). CCC 2019 better identified CCM in early-stage cirrhosis (Child-Pugh A), whereas Montreal 2005 was more sensitive in advanced stages (Child-Pugh C).</p><p><strong>Conclusion: </strong>CCM prevalence varies by diagnostic criteria and cirrhosis severity. Further studies are needed to determine the clinical relevance and prognostic value of each criterion.</p><p><strong>Prospero registration number: </strong>CRD42024511527.</p>","PeriodicalId":93875,"journal":{"name":"Annals of Saudi medicine","volume":"45 4","pages":"270-293"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cirrhotic cardiomyopathy: a systematic review and meta-analysis of prevalence across various diagnostic approaches.\",\"authors\":\"Mohammed Ewid, Suliman Alsagaby, Abdulsalam Al-Ruqi, Odi Al-Shamikh, Abdulelah Aljohani, Mariam Safwan Bourgleh, Moaz Safwana\",\"doi\":\"10.5144/0256-4947.2025.270\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction associated with liver cirrhosis, yet no consensus exists on standardized diagnostic criteria. We aimed to assess CCM prevalence using several guidelines.</p><p><strong>Methods: </strong>A systematic search of four databases (PubMed, Embase, Google Scholar, and EBSCO) identified observational studies reporting CCM prevalence in cirrhotic patients based on the three criteria: the World Congress of Gastroenterology (Montreal 2005), the American Society of Echocardiography (ASE 2009), and the Cirrhotic Cardiomyopathy Consortium (CCC 2019). A random-effects meta-analysis and subgroup analyses were performed using R Studio.</p><p><strong>Results: </strong>Seventy-six studies including 7445 patients were analyzed. Overall pooled CCM prevalence was 48% (95% CI: 44-52%, I<sup>2</sup>=97%). Prevalence was highest using Montreal 2005 (51%), followed by ASE 2009 (45%) and CCC 2019 (45%). CCC 2019 better identified CCM in early-stage cirrhosis (Child-Pugh A), whereas Montreal 2005 was more sensitive in advanced stages (Child-Pugh C).</p><p><strong>Conclusion: </strong>CCM prevalence varies by diagnostic criteria and cirrhosis severity. Further studies are needed to determine the clinical relevance and prognostic value of each criterion.</p><p><strong>Prospero registration number: </strong>CRD42024511527.</p>\",\"PeriodicalId\":93875,\"journal\":{\"name\":\"Annals of Saudi medicine\",\"volume\":\"45 4\",\"pages\":\"270-293\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Saudi medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5144/0256-4947.2025.270\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Saudi medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5144/0256-4947.2025.270","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Cirrhotic cardiomyopathy: a systematic review and meta-analysis of prevalence across various diagnostic approaches.
Background: Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction associated with liver cirrhosis, yet no consensus exists on standardized diagnostic criteria. We aimed to assess CCM prevalence using several guidelines.
Methods: A systematic search of four databases (PubMed, Embase, Google Scholar, and EBSCO) identified observational studies reporting CCM prevalence in cirrhotic patients based on the three criteria: the World Congress of Gastroenterology (Montreal 2005), the American Society of Echocardiography (ASE 2009), and the Cirrhotic Cardiomyopathy Consortium (CCC 2019). A random-effects meta-analysis and subgroup analyses were performed using R Studio.
Results: Seventy-six studies including 7445 patients were analyzed. Overall pooled CCM prevalence was 48% (95% CI: 44-52%, I2=97%). Prevalence was highest using Montreal 2005 (51%), followed by ASE 2009 (45%) and CCC 2019 (45%). CCC 2019 better identified CCM in early-stage cirrhosis (Child-Pugh A), whereas Montreal 2005 was more sensitive in advanced stages (Child-Pugh C).
Conclusion: CCM prevalence varies by diagnostic criteria and cirrhosis severity. Further studies are needed to determine the clinical relevance and prognostic value of each criterion.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
